Affordable Access

Access to the full text

18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes

  • Tsai, Richard M.1
  • Bejanin, Alexandre1
  • Lesman-Segev, Orit1
  • LaJoie, Renaud1
  • Visani, Adrienne1
  • Bourakova, Viktoriya1
  • O’Neil, James P.2
  • Janabi, Mustafa2
  • Baker, Suzanne2
  • Lee, Suzee E.1
  • Perry, David C.1
  • Bajorek, Lynn1
  • Karydas, Anna1
  • Spina, Salvatore1
  • Grinberg, Lea T.1
  • Seeley, William W.1
  • Ramos, Eliana M.3
  • Coppola, Giovanni3
  • Gorno-Tempini, Maria Luisa1
  • Miller, Bruce L.1
  • And 4 more
  • 1 University of California at San Francisco, Memory and Aging Center, 675 Nelson Rising Lane, Suite 190, San Francisco, CA, USA , San Francisco (United States)
  • 2 Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, USA , Berkeley (United States)
  • 3 University of California, Departments of Psychiatry and Neurology, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, Los Angeles, CA, USA , Los Angeles (United States)
  • 4 University of California at Berkeley, Helen Wills Neuroscience Institute, Berkeley, USA , Berkeley (United States)
Published Article
Alzheimer's Research & Therapy
BioMed Central
Publication Date
Jan 31, 2019
DOI: 10.1186/s13195-019-0470-7
Springer Nature


BackgroundThe tau positron emission tomography (PET) ligand 18F-flortaucipir binds to paired helical filaments of tau in aging and Alzheimer’s disease (AD), but its utility in detecting tau aggregates in frontotemporal dementia (FTD) is uncertain.MethodsWe performed 18F-flortaucipir imaging in patients with the FTD syndromes (n = 45): nonfluent variant primary progressive aphasia (nfvPPA) (n = 11), corticobasal syndrome (CBS) (n = 10), behavioral variant frontotemporal dementia (bvFTD) (n = 10), semantic variant primary progressive aphasia (svPPA) (n = 2) and FTD associated pathogenic genetic mutations microtubule-associated protein tau (MAPT) (n = 6), chromosome 9 open reading frame 72 (C9ORF72) (n = 5), and progranulin (GRN) (n = 1). All patients underwent MRI and β-amyloid biomarker testing via 11C-PiB or cerebrospinal fluid. 18F-flortaucipir uptake in patients was compared to 53 β-amyloid negative normal controls using voxelwise and pre-specified region of interest approaches.ResultsOn qualitative assessment, patients with nfvPPA showed elevated 18F-flortacupir binding in the left greater than right inferior frontal gyrus. Patients with CBS showed elevated binding in frontal white matter, with higher cortical gray matter uptake in a subset of β-amyloid-positive patients. Five of ten patients with sporadic bvFTD demonstrated increased frontotemporal binding. MAPT mutation carriers had elevated 18F-flortaucipir retention primarily, but not exclusively, in mutations with Alzheimer’s-like neurofibrillary tangles. However, tracer retention was also seen in patients with svPPA, and the mutations C9ORF72, GRN predicted to have TDP-43 pathology. Quantitative region-of-interest differences between patients and controls were seen only in inferior frontal gyrus in nfvPPA and left insula and bilateral temporal poles in MAPT carriers. No significant regional differences were found in CBS or sporadic bvFTD. Two patients underwent postmortem neuropathological examination. A patient with C9ORF72, TDP-43-type B pathology, and incidental co-pathology of scattered neurofibrillary tangles in the middle frontal, inferior temporal gyrus showed corresponding mild 18F-flortaucipir retention without additional uptake matching the widespread TDP-43 type B pathology. A patient with sporadic bvFTD demonstrated punctate inferior temporal and hippocampus tracer retention, corresponding to the area of severe argyrophilic grain disease pathology.Conclusions18F-flortaucipir in patients with FTD and predicted tauopathy or TDP-43 pathology demonstrated limited sensitivity and specificity. Further postmortem pathological confirmation and development of FTD tau-specific ligands are needed.

Report this publication


Seen <100 times